

IL-4 polymorphism influences susceptibility to *Pneumocystis jirovecii* pneumonia in HIV-positive patients

Agnieszka Wójtowicz^a, Stéphanie Bibert^a, Patrick Taffé^b,
Enos Bernasconi^c, Hansjakob Furrer^d, Huldrych F. Günthard^{e,f},
Matthias Hoffmann^g, Michael Osthoff^h, Matthias Cavassini^{a,*},
Pierre-Yves Bochud^{a,*}, the Swiss HIV Cohort Study[†]

Objectives: *Pneumocystis jirovecii* pneumonia (PJP) is an important cause of morbidity and mortality in HIV-positive patients. Polymorphisms in immune genes are increasingly reported to influence susceptibility to fungal infections. We analysed the role of 21 single nucleotide polymorphisms from 19 candidate genes on PJP development in patients from the Swiss HIV Cohort Study.

Design and methods: The analysis included patients with a nadir CD4⁺ T-cell count less than 200 cells/μl, divided into a discovery ($N = 1645$) and a replication ($N = 1861$) cohort. The associations were analysed by using cumulative incidence curves as well as competing risk regression over 18 years, starting from the estimated date of HIV infection, considering death a competing risk, with censoring at lost follow-up, and assuming the dominant mode of inheritance.

Results: The minor allele of rs2243250 in IL-4 was associated with the risk of PJP in the discovery cohort (cumulative incidence 0.18 versus 0.12, $P = 0.002$). This association was replicated in the validation cohort (0.16 versus 0.12, $P = 0.02$). It was still significant in multivariate models, adjusted for HIV transmission mode, viral load, CD4⁺ T cells slope, age, antiretroviral therapy, tobacco smoking, hepatitis C virus coinfection, year of cohort entry and PJP prophylaxis (global subhazard ratio 1.42, 95% confidence interval 1.17–1.73, $P = 0.0004$).

Conclusion: Our data suggest rs2243250, a single nucleotide polymorphism known to influence IL-4 production, is associated with susceptibility to PJP in HIV-positive patients.

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc.

AIDS 2019, **33**:1719–1727

Keywords: genetic susceptibility, HIV infection, immunity, IL-4, *Pneumocystis jirovecii* pneumonia

^aDepartment of Medicine, Infectious Diseases Service, ^bInstitute for Social and Preventive Medicine, University Hospital and University of Lausanne, Lausanne, ^cDivision of Infectious Diseases, Regional Hospital of Lugano, Lugano, ^dDepartment of Infectious Diseases, Bern University Hospital and University of Bern, Bern, ^eDivision of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich and University of Zürich, ^fInstitute of Medical Virology, University of Zürich, Zürich, ^gDivision of Infectious Diseases and Hospital Epidemiology, Department of Internal Medicine, Cantonal Hospital St.Gallen, St.Gallen, and ^hDivision of Infectious Diseases and Hospital Epidemiology and Department of Internal Medicine, University Hospital Basel, Basel, Switzerland.

Correspondence to Pierre-Yves Bochud, Infectious Diseases Service, Department of Medicine, University Hospital and University of Lausanne (CHUV), Rue du Bugnon 46, CH-1011 Lausanne, Switzerland.

Tel: +41 21 314 43 79; fax: +41 21 314 10 33; e-mail: Pierre-Yves.Bochud@chuv.ch

* Matthias Cavassini and Pierre-Yves Bochud contributed equally to the article.

† Members of the Swiss HIV Cohort Study are indicated in Acknowledgments section.

Received: 19 April 2019; revised: 22 May 2019; accepted: 24 May 2019.

DOI:10.1097/QAD.0000000000002283

ISSN 0269-9370 Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Introduction

Pneumocystis jirovecii is an opportunistic fungus causing severe pneumonia in HIV/AIDS and other populations of immunosuppressed patients [1]. It is one of the most common AIDS-defining conditions and an important cause of AIDS-related deaths [2–4]. *P. jirovecii* pneumonia (PJP) typically manifests among individuals with a CD4⁺ T-cell count of less than 200/μl, in particular when the HIV viral load is elevated [5]. Other factors such as ethnicity [6] and HIV transmission mode [7] have been reported to alter susceptibility to PJP in some studies, but this was not universally confirmed [8].

Increasing evidence suggests that polymorphisms in host immune genes influence the course of infections due to fungal pathogens. Single nucleotide polymorphisms (SNPs) in genes encoding pattern recognition receptors (PRRs) such as pentraxin 3 [9–11] and Dectin-1 [12–14] are emerging as reliable predictors of the future occurrence of invasive aspergillosis among onco-hematological patients as well as hematopoietic stem cell and solid organ transplant recipients [15,16]. Similarly, polymorphisms in genes encoding cytokines were associated with both invasive aspergillosis (IL1B [17,18]) and candidiasis (TNFα [19], IL-4 [20]). Fewer studies examined the role of immune gene polymorphisms in susceptibility to PJP or AIDS progression. One study associated low producing mannose binding lectin 2 (MBL2) haplotype [21] with PJP infection in a small cohort of HIV-infected individuals. Other polymorphisms apparently associated with PJP in HIV-positive patients are in fact markers of rapid progression to AIDS [22–24].

In this study, we analysed the role of polymorphisms from 21 candidate genes encoding relevant fungal PRRs and cytokines/chemokines with regards to the predisposition to PJP in the patients from the Swiss HIV Cohort Study (SHCS).

Methods

Study cohort and design

The SHCS (www.shcs.ch) is a prospective observational multicenter cohort of seven Swiss hospitals (Basel, Bern, Geneva, Lausanne, Zurich, Lugano and St. Gallen [25]). More than 20 000 HIV-infected patients have been enrolled in Switzerland since 1988 [25,26]. The clinical stage of the patients was defined according to the 1993 classification system for HIV infection of the Centers for Disease Control and Prevention [27]. Demographic characteristics including age, duration of HIV infection, CD4⁺ T-cell count nadir, opportunistic infections, HIV maximal viral load and antiretroviral therapy used were extracted from the SHCS clinical database [28]. Written

informed consent was obtained from all patients, including consent for the genetic studies. All patients whose CD4⁺ T-cell count was of less than 200 cells/μl for at least 3 months were selected. Patients were randomly stratified into a discovery group and a validation group at a 1 : 1 ratio. Additional patients who were entered into the cohort after the randomization process were added to the validation group.

Definite and presumptive PJP infections were defined according to standard definitions [29]. Briefly, a definitive diagnosis required the identification of the pathogen from respiratory samples by cytology/microscopy or histology. The presumptive diagnosis was made on a combination of clinical signs/symptoms and radiological findings (<http://www.shcs.ch/122-4-cdc-category-c-diagnoses#4.2.1>). The CD4⁺ T-cell loss rate was calculated for each individual using a linear regression of time on the square root of CD4⁺ T-cell counts as described elsewhere [30]. Unknown HIV-infection dates were estimated by using a joint back calculation model as described elsewhere [31].

Genotyping

A total of 21 SNPs from 19 genes were selected based on a systematic literature review, including SNPs previously associated with fungal infections. Genomic DNA was extracted from cell pellets or whole blood with use of a MagNA Pure LC DNA Isolation Kit (Roche Applied Science, Munich, Germany) according to the manufacturer's protocols. The SNPs were part of a customized Golden Gate Genotyping Assay (Veracode technology, Illumina) or were genotyped using a Competitive Allele Specific PCR system (KBioscience/LGC Genomics; <http://www.lgcgenomics.com>). Genotype data were analyzed on a BeadXpress Reader or a KlusterKaller software (KBioscience/LGC Genomics) according to the standard protocols and quality controls [32].

Statistical analysis

Statistical analyses were performed in Stata 15.1 (StataCorp LLC, College Station, Texas, USA). Cumulative incidence of PJP was assessed over a 18 years period starting at the estimated date of the HIV infection with censoring at last follow-up and considering death as a competing event, by using `stcrreg` implemented in Stata. For simplicity a dominant mode of inheritance was assumed for each SNP and the first episode of PJP was considered. Multivariate analyses were performed by using `stcrreg`, with adjustment for co-variables possibly associated with PJP, considering a cut-off *P* value of 0.1 in the univariate analyses. CD4⁺ T-cell counts were accounted for either by using the CD4⁺ slope before antiretroviral therapy (as described above) or as a time-varying covariable. Other variables such as hepatitis C virus (HCV) or hepatitis B virus infection, as well as antiretroviral and anti-*Pneumocystis carinii* pneumonia (PCP) drugs were accounted for either as present/absent at any time during follow-up (e.g demographic tables) or

as time-varying covariables (time-dependent analyses). Associations were first analysed among patients from the discovery cohort and, when significant, replicated in the validation cohort. The linkage disequilibrium and Hardy–Weinberg equilibrium (HWE) tests were assessed by using the *plink* and *hwe* softwares implemented in Stata. Bonferroni's correction was used to adjust data for the number of tests included in the models. MBL2 haplotypes were phased using PHASE software version 2.1 (University of Washington, Seattle, Washington, USA).

Results

A total of 3506 Caucasian individuals were included (1645 in the discovery and 1861 in the replication study, Table 1), among whom 470 developed PJP (413 definite and 57 presumptive). Patient characteristics were equally distributed in the discovery and the replication studies, with a mean age of 33 years (range 10–74) at time of cohort entry, a male predominance (77%), a mean CD4⁺ T-cell nadir count of 90.5 cells/ μ l (range 0–199) and a mean maximal log viral load of 5.20 copies/ml (range 1–8). HIV infection was acquired by male–male sexual contact in 40%, by heterosexual contact in 31% and by intravenous drug use in 26%.

All the SNPs were at the HWE equilibrium and had minor allele frequencies (MAF) comparable to the ones known for the white population (Supplementary Table S1, <http://links.lww.com/QAD/B490>). In the discovery cohort, associations ($P < 0.05$) were observed for four polymorphisms in four genes, including rs2243250 in IL-4 [cumulative incidence (CI) 0.18 versus 0.12, $P = 0.002$, Fig. 1a], rs4252125 in plasminogen (CI 0.11 versus 0.16, $P = 0.005$), rs16910526 in Dectin-1 (CLEC7A; CI 0.08 versus 0.14, $P = 0.01$) and rs17886395 in surfactant protein A (CI 0.10 versus 0.15, $P = 0.03$, Table 2).

Among those, only one association was significant after Bonferroni correction for multiple testing (21 tests, rs2243250 in IL-4). This association was also significant in the replication cohort (CI 0.16 versus 0.12, $P = 0.02$; Fig. 1b). Furthermore, the association was still significant in a multivariable regression model in both the discovery (subhazard ratio, SHR = 1.43, 95% confidence interval 1.07–1.92, $P = 0.02$) and replication (SHR = 1.42, 95% confidence interval 1.08–1.85, $P = 0.01$, Table 3) studies. In the combined cohorts after adjustment for the maximal HIV viral load, antiretroviral therapy, CD4⁺ slope, age at estimated time of HIV infection, PJP prophylaxis, tobacco use, HCV coinfection, period of cohort entry as well as the mode of HIV transmission, the association was more significant (SHR = 1.42, 95% confidence interval 1.17–1.73, $P = 0.0004$). The association between PJP and rs2243250 were significant when the

Table 1. Demographic characteristic of the patients.

Variable	Discovery, N = 1645	Replication, N = 1861	All patients, N = 3506
	N (%)	N (%)	N (%)
Age at cohort entry (mean years; range)	32.5 (10–73)	33 (13–74)	32.8 (10–74)
Male sex	1273 (77)	1425 (77)	2698 (77)
ART/HAART therapy at any time	1641 (99)	1856 (99)	3495 (99)
HIV maximal viral load (mean RNA log ₁₀ copies/ml; range) ^a	5.20 (2–8)	5.21 (1–8)	5.20 (1–8)
Nadir CD4 ⁺ T-cell count (mean cells/ μ l; range) ^b	89.9 (0–199)	91.0 (0–199)	90.5 (0–199)
CD4 ⁺ slope before ART/HAART initiation (mean; range) ^c	–2.12 (–7–1)	–2.16 (–6–2)	–2.14 (–7–2)
PJP ^d	240 (15)	260 (14)	500 (14)
At presentation	135	162	297
During follow-up	105	98	203
Type of HIV transmission			
Male–male sexual contact	681 (41)	725 (39)	1406 (40)
Heterosexual contact	462 (28)	611 (33)	1071 (31)
Intravenous drug user	446 (27)	462 (25)	908 (26)
Other/unknown	58 (4)	63 (3)	121 (3)
HCV coinfection ^e	551 (33)	616 (33)	1165 (33)
Active HBV infection ^f	64 (4)	82 (4)	146 (4)
Tobacco smokers ^g	985 (60)	1118 (60)	2103 (60)

ART, antiretroviral therapy; HBV, hepatitis b virus; HCV, hepatitis C virus; PJP, *Pneumocystis jirovecii* pneumonia.

^aMean maximal HIV RNA load, was missing in two and seven patients in the discovery and replication cohort, respectively.

^bLowest level of a CD4⁺ T-cell count.

^cRate of CD4⁺ depletion in the absence of HAART, was missing in 24 and 25 patients in the discovery and replication cohort, respectively.

^dAmong PJP cases, 202 (84%) were definitive and 38 (16%) presumptive in the discovery cohort and 237 (91%) definitive and 23 (9%) presumptive in the replication cohort.

^eReflected by HCV serology.

^fHBV serostatus, defined by the presence of HBsAg in the blood.

^gAt cohort entry: more than 10 packet unit year.




Fig. 1. Cumulative incidence of *Pneumocystis jirovecii* pneumonia according to IL-4 rs2243250 in the discovery [(a) $n = 1426$ patients with available genotypes] and replication [(b) $n = 1832$] studies. Graphs were performed using the cumulative incidence function in *stcurve* after competing risk regression with *stcrred*, considering death as competing risk (Stata).

Table 2. Cumulative incidence of *Pneumocystis jirovecii* pneumonia according to candidate gene polymorphisms in HIV-positive patients from Swiss HIV Cohort Study cohort.

Gene	rs number	nt aa change	MAF	Discovery study, N = 1645				Replication study, N = 1861			
				N ^a	Cum. Incid.		p ^b	N ^a	Cum. Incid.		p ^b
					WT	MUT			WT	MUT	
Pattern recognition receptors											
<i>CLEC7A</i>	rs16910526	Y238X	0.08	1639	0.08	0.14	0.01				
<i>TLR3</i>	rs3775291	L412F	0.29	1632	0.15	0.12	0.1				
<i>TLR1</i>	rs5743611	R80T	0.08	1631	0.15	0.13	0.3				
<i>MBL2</i>	Haplotype	Low MBL	0.27	1548	0.11	0.14	0.3				
<i>PTX3</i>	rs3816527	A48D	0.40	1531	0.13	0.14	0.5				
<i>TLR2</i>	rs5743708	R753Q	0.02	918	0.12	0.14	0.7				
<i>TLR6</i>	rs5743810	S249P	0.36	1623	0.14	0.13	0.8				
<i>TLR1</i>	rs5743604	S602I	0.33	1622	0.13	0.13	0.8				
<i>TLR4</i>	rs4986790	D299G	0.05	1623	0.13	0.13	0.9				
Cytokines/Chemokines and other genes											
<i>IL4</i>	rs22433250 ^c	-590 C/T	0.14	1426	0.18	0.12	0.002 ^d	1832	0.16	0.12	0.02
<i>PLG</i>	rs4252125	D472N	0.31	1632	0.11	0.16	0.005 ^e	1839	0.14	0.12	0.2
<i>SPA2</i>	rs17886395	A91P	0.14	1590	0.10	0.15	0.03				
<i>IL1A</i>	rs1800587	-889 C/T	0.28	1598	0.15	0.12	0.05				
<i>TNFα</i>	rs1800629	-308 G/A	0.13	1465	0.11	0.14	0.08				
<i>IL1B</i>	rs1143627	-31 T/C	0.34	1633	0.12	0.15	0.1				
<i>IL4RA</i>	rs1805015	S503P	0.15	1624	0.15	0.12	0.1				
<i>IL19</i>	rs1800896	-1082 A/G	0.44	1634	0.13	0.14	0.5				
<i>CXCL10</i>	rs3921	1642 G/C	0.43	1634	0.13	0.14	0.6				
<i>DEFB1</i>	rs1800972	-44 C/G	0.19	1612	0.14	0.13	0.7				
<i>FCGR2A</i>	rs1801274	R131H	0.48	1614	0.14	0.13	0.9				

CI, confidence interval; *CLEC7A*, C-type lectin domain 7, also known as Dectin-1; *CXCL10*, CXC-chemokine ligand-10; *DEFB1*, human beta-defensin 1; *FCGR2A*, Fc Fragment of IgG receptor IIa; HR, hazard ratio; IL, interleukin; *IL4RA*, *IL4* receptor subunit alpha; LD, linkage disequilibrium; MAF, minor allele frequency; *MBL2*, mannose binding lectin 2; PJP, *Pneumocystis jirovecii* pneumonia; *PLG*, plasminogen; *PTX3*, pentraxin 3; SHCS, Swiss HIV cohort study; *SPA2*, surfactant protein A2; *TLR*, Toll-like receptor; WT, wild type.

^aN stands for the number of available genotypes for each SNP (after quality testing).

^bAssociations were analysed by using *stcrreg*, considering dominant mode of inheritance (patients homo- and heterozygous for the rare allele are compared to the others).

^cBecause some genotypes were missing, the association was also run for rs2070874, which is in strong LD with rs2243250 ($R^2 = 0.96$). The *P* value for rs2243250 was 0.0008.

^d $P = 0.047$ and $P = 0.016$ for rs2243250 and rs2070874, respectively, after Bonferroni correction (21 tests).

^e $P = 0.099$ after Bonferroni correction (21 tests).

presumptive PJP cases were removed from the model (SHR = 1.36, 95% confidence interval 1.10–1.68, $P = 0.004$), and when $CD4^+$ T cells were accounted for as a time-dependent covariates instead of a slope (SHR = 1.41, 95% confidence interval 1.14–1.75, $P = 0.00016$, Supplementary Table 3, <http://links.lww.com/QAD/B490>).

The association with rs4252125 in plasminogen tended to be associated after corrections for multiple tests (21 tests, $P = 0.1$) but was not replicated.

Discussion

In this study, we show for the first time an association between a SNP in the *IL-4* gene and susceptibility to PJP. This association discovered in a study of 1645 patients was validated in a replication cohort of 1861 individuals. It was still present in multivariate

analyses accounting for potential confounding factors such as $CD4^+$ T-cell decline over time. It is further supported by several lines of evidence for a key role of *IL-4*, a cytokine, in the adaptive immune responses against *P. jirovecii*.

The *IL-4* gene located on chromosome 5q31.1 encodes *IL-4*, a polyfunctional cytokine produced by activated T cells, type 2 innate lymphoid cells and mast cells, which is involved in adaptive immunity [33]. Its biological activity is mediated through a heterodimeric structured receptor (*IL-4R*) consisting of *IL-4Rα* together with either a γ chain (type1 receptor) or a *IL13R-α-1* (type2 receptor) molecule (reviewed in [34,35]). *IL-4* promotes the differentiation of $CD4^+$ T cells into the Th2 phenotype (also mediated by *IL-13* and *IL-10*), leading to B-cell activation and production of neutralizing antibodies such as IgE and IgG1 [34]. It also counterbalances the Th1 phenotype (mediated by $IFN\gamma$ and $TNF\alpha$) and subsequent activation of cell-mediated immunity and phagocytic activity [36].

Table 3. Multivariate analysis of factors associated with *Pneumocystis jirovecii* pneumonia.

	Discovery study ^a , N = 1424			Replication study ^a , N = 1825			All patients ^a , N = 3210		
	SHR	95% CI	P ^a	SHR	95% CI	P ^a	SHR	95% CI	P ^a
Age ^b	1.00	0.99–1.02	0.8	1.01	1.00–1.02	0.06	1.01	1.00–1.02	0.1
Male sex	0.78	0.53–1.15	0.2	0.95	0.69–1.30	0.7	0.87	0.68–1.11	0.3
CD4 ⁺ slope ^c	0.17	0.11–0.26	<0.0001	0.16	0.11–0.24	<0.0001	0.17	0.13–0.22	<0.0001
Maximal HIV RNA (log copies/ml)	1.37	1.11–1.69	0.003	1.67	1.38–2.01	<0.0001	1.53	1.33–1.76	<0.0001
Type of HIV transmission									
MSM	Ref.			Ref.			Ref.		
Heterosexual	1.22	0.87–1.71	0.2	0.98	0.72–1.34	0.9	1.09	0.87–1.37	0.5
Intravenous drug use	1.00	0.61–1.63	1.0	0.72	0.49–1.04	0.08	0.85	0.63–1.14	0.3
Other	1.64	0.92–2.91	0.09	1.27	0.77–2.11	0.3	1.39	0.96–2.03	0.09
Cohort entry (years)									
<1995	Ref.			Ref.			Ref.		
1995–2000	0.98	0.70–1.38	0.9	0.83	0.60–1.14	0.3	0.90	0.71–1.13	0.4
2001–2005	0.77	0.49–1.20	0.2	0.92	0.66–1.27	0.6	0.90	0.70–1.15	0.4
>2005	0.32	0.04–2.63	0.3	0.20	0.06–0.69	0.01	0.25	0.09–0.69	0.008
PJP prophylaxis ^d	0.44	0.32–0.60	<0.0001	0.31	0.24–0.40	<0.0001	0.36	0.30–0.44	<0.0001
ART/HAART ^e	0.79	0.75–0.83	<0.0001	0.75	0.71–0.80	<0.0001	0.77	0.74–0.80	<0.0001
HCV coinfection ^e	0.93	0.87–1.00	0.05	0.94	0.89–0.99	0.01	0.93	0.90–0.97	0.001
Tobacco smoking ^f	0.77	0.57–1.03	0.08	0.89	0.68–1.15	0.4	0.83	0.68–1.01	0.06
IL-4 rs2243250 TT/TC versus CC ^g	1.43	1.07–1.92	0.02	1.42	1.08–1.85	0.01	1.42	1.17–1.73	0.0004

ART, antiretroviral treatment; CI, confidence interval; HCV, hepatitis C virus; OR, odds ratio; PJP, *Pneumocystis jirovecii* pneumonia; SHR, subhazard ratio (competing risk regression).

^aVariables potentially associated with *Pneumocystis carinii* pneumonia (cut-off $P < 0.1$ by univariate testing, Supplemental Table 2, <http://links.lww.com/QAD/B490>) were entered into the multivariate analysis, with age and sex forced into the model. The number of patients is slightly lower than the number of patients included in the studies because some covariables are missing for some patients (refer to Table 1 for details).

^bAt estimated HIV infection date (refer to Methods section); SHR is calculated per 1 additional year of age.

^cRate of CD4⁺ depletion before HAART (refer to Methods section); Note: similar results were found when CD4⁺ were accounted for as a time-dependent covariates (refer to Supplemental Table 3, <http://links.lww.com/QAD/B490>).

^dAt any time during follow-up.

^eTime-dependent covariates.

^fAt cohort entry: more than 10 U packet-year.

^gGenetic associations are for the dominant mode of inheritance (patients homozygous and heterozygous for the rare allele are compared with the other). Because some genotypes were missing for rs2243250 in the discovery study, the association was also run for rs2070874, which is in strong LD with rs2243250 ($R^2 = 0.96$): OR = 1.37, 95% CI 1.05–1.80, $P = 0.02$ (model including 1629 patients).

A number of studies have shown that immunity against *Pneumocystis* spp. is mediated by both Th1 and Th2 responses [37]. Inhibition of the Th1 response by using anti-TNF α antibodies induced decreased [36] or delayed [38] pathogen clearance in two different mice models of PCP. Reversely, stimulation of Th1 responses by using an adenoviral vector encoding IFN γ protected T cells depleted mice from PCP [39] and recombinant IFN γ increased survival in a rat model of PCP. Inhibition of B cells in mice by using antibodies targeting CD20 also leads to increased susceptibility for PJP [40]. The risk of *Pneumocystis* spp. infections in humans is increased in patients with primary immune deficiencies, such as X-linked hyper-IgM syndrome [41], as well as in patients treated with monoclonal antibodies against the CD20+ antigen on B cells (rituximab or obinutuzumab [42,43]), the CD52 antigen on B and T cells (alemtuzumab [44]), or with Bruton's tyrosine kinase inhibitor (ibrutinib [45]).

Several studies suggested that the presence of the -590T allele in rs2243250 is associated with increased serum or plasma IL-4 levels [46–49], although this was not universally confirmed [50,51]. Higher IL-4 gene expression may result

from a new binding site for nuclear factor of activated T cells, the main transcription factor for the IL-4 expression, at the nucleotide position -590 (Supplemental Fig. S2, <http://links.lww.com/QAD/B490>) [52]. Conversely, the -590T allele was associated with reduced IFN γ and TNF α expression and/or production by human immune cells stimulated with phorbol myristate acetate/Ionomycin (including neutrophils, monocytes and lymphocytes), suggesting that higher IL-4 production could counteract Th1 responses, leading to decreased *Pneumocystis* spp. clearance [46].

Altogether, this data suggest that increased IL-4 levels in -590T allele carriers result in increased susceptibility to infections mainly as a result from reduced Th1 responses, and that this defect cannot be adequately compensated by a concomitant or subsequent increase in Th2 responses. Consistent with this hypothesis, the -590T allele was associated with an increased risk of vulvo-vaginal candidiasis, as well as increased vaginal IL-4 levels, in a cohort of 85 Latvian women [53] and a higher risk of paracoccidioidomycosis in a cohort of 81 Brazilian individuals [51]. In a cohort of adult leukemia patients,

the -590T allele was protective for hepatosplenic candidiasis, as a possible result of diminished immune reconstitution after neutropenia [20]. In addition, numerous studies associated the -590T variant with susceptibility to pathogens other than fungi, such as respiratory syncytial virus (RSV) [54–57], *Plasmodium falciparum* [58], *Brucella* spp. [59], *Clostridium difficile* [60] and bacteria causing periodontitis [61–65].

Also consistent with this hypothesis, animal studies showed that IL-4 deficiency is associated with protection against fungal, mycobacterial and parasitic infections. In a cyclophosphamide-induced mice model of invasive aspergillosis, mice deficient in IL-4 had increased survival [66] and increased broncho-alveolar lavage IFN γ levels, compared to WT mice. In a mouse model of tuberculosis, IL-4-deficient mice had decreased disease severity and increased TNF α lung expression compared to WT mice [67]. In a mouse model of RSV infection, overexpression of IL-4 was associated with decreased viral clearance and neutralization of IL-4 with a reduced illness score [68,69]. In a murine model of *Leishmania major* infection, parasite clearance was positively correlated with the production of IFN γ (Th1) and negatively correlated with that of IL-4, IL-5 and IL-13 (Th2) [70].

Like other genetic association studies, our study has some limitations. The date of HIV-1 infection was estimated by using a joint back calculation model in seroprevalent patients [31]. Although it is by far the largest association study for PJP infection, our study may have failed to detect associations with rare variants, such as those in Dectin-1 (MAF = 0.08), Toll-like receptor 1 (TLR1) (MAF = 0.08) or TLR4 (MAF = 0.05), which have been associated with susceptibility to infections due to other fungi. Our study did not replicate a previously reported association with MBL2 low expression haplotypes [21], despite reasonable power to do so (>80% power to detect an association with hazard ratio = 1.5; Supplemental Table S1, <http://links.lww.com/QAD/B490>). Despite substantial evidence for a role for rs2243250 on IL-4 production, baseline IL-4 levels have not been measured in study patients to further support genetic associations. In addition, while the SHCS is a well established longitudinal cohort with robust follow-up, patients management strategies including prophylaxis and antiretroviral treatment have been evolving over year. Yet, despite the limitations, association with IL-4 SNP was still significant in multivariate models accounting for prophylaxis and different periods of cohort entry.

In conclusion, this data demonstrates an association between PJP and the presence of the interleukin-4-590T/C polymorphism in a large cohort of HIV patients. This SNP may influence the Th2/Th1 responses required for appropriate immunity against *Pneumocystis* spp. and increase susceptibility to infection in HIV-positive patients with low level of CD4⁺ T cells.

Acknowledgements

We thank all the study nurses and SHCS members who were engaged in the data collection and provided care for the patients as well as technical assistants and all the other laboratory members that were in charge for sample shipment and DNA extraction.

Members of the Swiss HIV Cohort Study: Anagnostopoulos A, Battegay M, Bernasconi E, Böni J, Braun DL, Bucher HC, Calmy A, Cavassini M, Ciuffi A, Dollenmaier G, Egger M, Elzi L, Fehr J, Fellay J, Furrer H (Chairman of the Clinical and Laboratory Committee), Fux CA, Günthard HF (President of the SHCS), Haerry D (deputy of 'Positive Council'), Hasse B, Hirsch HH, Hoffmann M, Hösli I, Huber M, Kahlert C, Kaiser L, Keiser O, Klimkait T, Kouyos RD, Kovari H, Ledergerber B, Martinetti G, Martinez de Tejada B, Marzolini C, Metzner KJ, Müller N, Nicca D, Paioni P, Pantaleo G, Perreau M, Rauch A (Chairman of the Scientific Board), Rudin C (Chairman of the Mother & Child Substudy), Scherrer AU (Head of Data Centre), Schmid P, Speck R, Stöckle M, Tarr P, Trkola A, Vernazza P, Wandeler G, Weber R, Yerly S.

The study has been financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (grant no. 177499), by SHCS project no. 803 and by the SHCS research Foundation. This work was supported by research funding from the Leenaards Foundation, the Santos-Suarez Foundation and a Mériex Research Grant (MRG). PYB is recipient of grants from the Swiss National Science Foundation (32003B-127613, 320030-144054 and 33IC30_179636) and the European Union's Seventh Framework Program (FP7/2007–2013) under grant agreement no. HEALTH-2010–260338 (ALLFUN).

Conflicts of interest

There are no conflicts of interest.

References

1. Thomas CF Jr, Limper AH. **Pneumocystis pneumonia**. *N Engl J Med* 2004; **350**:2487–2498.
2. Llibre JM, Revollo B, Vanegas S, Lopez-Nunez JJ, Ornelas A, Marin JM, et al. **Pneumocystis jirovecii pneumonia in HIV-1-infected patients in the late-HAART era in developed countries**. *Scand J Infect Dis* 2013; **45**:635–644.
3. Siegel M, Masur H, Kovacs J. **Pneumocystis jirovecii pneumonia in human immunodeficiency virus infection**. *Semin Respir Crit Care Med* 2016; **37**:243–256.
4. Lee SH, Kim KH, Lee SG, Chen DH, Jung DS, Moon CS, et al. **Trends of mortality and cause of death among HIV-infected patients in Korea, 1990–2011**. *J Korean Med Sci* 2013; **28**:67–73.
5. Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, Morlat P, et al., Opportunistic Infections Project Team of the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE). **Is it safe to discontinue primary *Pneumocystis jirovecii* pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?** *Clin Infect Dis* 2010; **51**:611–619.

6. Stansell JD, Osmond DH, Charlebois E, LaVange L, Wallace JM, Alexander BV, *et al.* Predictors of *Pneumocystis carinii* pneumonia in HIV-infected persons. Pulmonary complications of HIV Infection Study Group. *Am J Respir Crit Care Med* 1997; **155**:60–66.
7. Kaplan JE, Hanson DL, Navin TR, Jones JL. Risk factors for primary *Pneumocystis carinii* pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. *J Infect Dis* 1998; **178**:1126–1132.
8. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, *et al.* Current epidemiology of *Pneumocystis pneumonia*. *Emerg Infect Dis* 2004; **10**:1713–1720.
9. Wojtowicz A, Lecompte TD, Bibert S, Manuel O, Rueger S, Berger C, *et al.* PTX3 polymorphisms and invasive mold infections after solid organ transplant. *Clin Infect Dis* 2015; **61**:619–622.
10. Cunha C, Aversa F, Lacerda JF, Busca A, Kurzai O, Grube M, *et al.* Genetic PTX3 deficiency and aspergillosis in stem-cell transplantation. *N Engl J Med* 2014; **370**:421–432.
11. Brunel AS, Wojtowicz A, Lamoth F, Spertini O, Neofytos D, Calandra T, *et al.* Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients with intensive chemotherapy. *Haematologica* 2018; **103**:e527–e530.
12. Cunha C, Di Ianni M, Bozza S, Giovannini G, Zagarella S, Zelante T, *et al.* Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. *Blood* 2010; **116**:5394–5402.
13. Chai LY, de Boer MG, van der Velden WJ, Plantinga TS, van Spruel AB, Jacobs C, *et al.* The Y238X stop codon polymorphism in the human beta-glucan receptor dectin-1 and susceptibility to invasive aspergillosis. *J Infect Dis* 2011; **203**:736–743.
14. Sainz J, Lupianez CB, Segura-Catena J, Vazquez L, Rios R, Oyonarte S, *et al.* Dectin-1 and DC-SIGN polymorphisms associated with invasive pulmonary aspergillosis infection. *PLoS One* 2012; **7**:e32273.
15. Wojtowicz A, Bochud PY. Host genetics of invasive *Aspergillus* and *Candida* infections. *Semin Immunopathol* 2015; **37**:173–186.
16. Wojtowicz A, Bochud PY. Risk stratification and immunogenetic risk for infections following stem cell transplantation. *Virulence* 2016; **7**:917–929.
17. Wojtowicz A, Gresnigt MS, Lecompte T, Bibert S, Manuel O, Joosten LA, *et al.* IL1B and DEFB1 polymorphisms increase susceptibility to invasive mold infection after solid-organ transplantation. *J Infect Dis* 2015; **211**:1646–1657.
18. Sainz J, Perez E, Gomez-Lopera S, Jurado M. IL1 gene cluster polymorphisms and its haplotypes may predict the risk to develop invasive pulmonary aspergillosis and modulate C-reactive protein level. *J Clin Immunol* 2008; **28**:473–485.
19. Wojtowicz A, Tissot F, Lamoth F, Orasch C, Eggimann P, Siegemund M, *et al.* Polymorphisms in tumor necrosis factor-alpha increase susceptibility to intra-abdominal *Candida* infection in high-risk surgical ICU patients. *Crit Care Med* 2014; **42**:e304–e308.
20. Choi EH, Foster CB, Taylor JG, Erichsen HC, Chen RA, Walsh TJ, *et al.* Association between chronic disseminated candidiasis in adult acute leukemia and common IL4 promoter haplotypes. *J Infect Dis* 2003; **187**:1153–1156.
21. Yanagisawa K, Ogawa Y, Uchiumi H, Gohda F, Mawatari M, Ishizaki T, *et al.* Gene polymorphisms of mannose-binding lectin confer susceptibility to *Pneumocystis pneumonia* in HIV-infected patients. *J Infect Chemother* 2015; **21**:769–775.
22. An P, Li R, Wang JM, Yoshimura T, Takahashi M, Samudralal R, *et al.* Role of exonic variation in chemokine receptor genes on AIDS: CCRL2 F167Y association with pneumocystis pneumonia. *PLoS Genet* 2011; **7**:e1002328.
23. An P, Penugonda S, Thorball CW, Bartha I, Goedert JJ, Donfield S, *et al.* Role of APOBEC3F gene variation in HIV-1 disease progression and pneumocystis pneumonia. *PLoS Genet* 2016; **12**:e1005921.
24. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. FcγRIIIa genotype predicts progression of HIV infection. *J Immunol* 2007; **179**:7916–7923.
25. Ledergerber B, von Overbeck J, Egger M, Luthy R. The Swiss HIV Cohort Study: rationale, organization and selected baseline characteristics. *Soz Präventivmed* 1994; **39**:387–394.
26. Sudre P, Rickenbach M, Taffe P, Janin P, Volkart AC, Francioli P, *et al.* Clinical epidemiology and research on HIV infection in Switzerland: the Swiss HIV Cohort Study 1988–2000. *Schweiz Med Wochenschr* 2000; **130**:1493–1500.
27. Centers for Disease Control and Prevention. 1993 Classification system for HIV infection and expanded surveillance case definition for acquired immunodeficiency syndrome (AIDS) among adolescents and adults. *MMWR Morb Mortal Wkly Rep* 1992; **41**:1–19.
28. Zellweger C, Opravil M, Bernasconi E, Cavassini M, Bucher HC, Schiffer V, *et al.* Long-term safety of discontinuation of secondary prophylaxis against *Pneumocystis pneumonia*: prospective multicentre study. *AIDS* 2004; **18**:2047–2053.
29. Ebner L, Walti LN, Rauch A, Furrer H, Cusini A, Meyer AM, *et al.* Clinical course, radiological manifestations, and outcome of *Pneumocystis jirovecii* pneumonia in HIV patients and renal transplant recipients. *PLoS One* 2016; **11**:e0164320.
30. Bochud PY, Hersberger M, Taffe P, Bochud M, Stein CM, Rodrigues SD, *et al.* Polymorphisms in Toll-like receptor 9 influence the clinical course of HIV-1 infection. *AIDS* 2007; **21**:441–446.
31. Taffe P, May M, Swiss HIV Cohort Study. A joint back calculation model for the imputation of the date of HIV infection in a prevalent cohort. *Stat Med* 2008; **27**:4835–4853.
32. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. *Bioinformatics* 2005; **21**:263–265.
33. Arai N, Nomura D, Villaret D, DeWaal Malefijt R, Seiki M, Yoshida M, *et al.* Complete nucleotide sequence of the chromosomal gene for human IL-4 and its expression. *J Immunol* 1989; **142**:274–282.
34. Paul WE. History of interleukin-4. *Cytokine* 2015; **75**:3–7.
35. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. *Annu Rev Immunol* 1999; **17**:701–738.
36. Chen W, Havell EA, Harmsen AG. Importance of endogenous tumor necrosis factor alpha and gamma interferon in host resistance against *Pneumocystis carinii* infection. *Infect Immun* 1992; **60**:1279–1284.
37. Steele C, Shellito JE, Kolls JK. Immunity against the opportunistic fungal pathogen *Pneumocystis*. *Med Mycol* 2005; **43**:1–19.
38. Kolls JK, Lei D, Vazquez C, Odom G, Summer WR, Nelson S, *et al.* Exacerbation of murine *Pneumocystis carinii* infection by adenoviral-mediated gene transfer of a TNF inhibitor. *Am J Respir Cell Mol Biol* 1997; **16**:112–118.
39. Kolls JK, Habetz S, Shean MK, Vazquez C, Brown JA, Lei D, *et al.* IFN-gamma and CD8+ T cells restore host defenses against *Pneumocystis carinii* in mice depleted of CD4+ T cells. *J Immunol* 1999; **162**:2890–2894.
40. Elsegeiny W, Eddens T, Chen K, Kolls JK. Anti-CD20 antibody therapy and susceptibility to *Pneumocystis pneumonia*. *Infect Immun* 2015; **83**:2043–2052.
41. Milledge J, Kakakios A, Gillis J, Fitzgerald DA. *Pneumocystis carinii* pneumonia as a presenting feature of X-linked hyper-IgM syndrome. *J Paediatr Child Health* 2003; **39**:704–706.
42. Martin-Garrido I, Carmona EM, Specks U, Limper AH. *Pneumocystis pneumonia* in patients treated with rituximab. *Chest* 2013; **144**:258–265.
43. Venhuizen AC, Hustinx WN, van Houte AJ, Veth G, van der Griend R. Three cases of *Pneumocystis jirovecii* pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma. *Eur J Haematol* 2008; **80**:275–276.
44. Kim SJ, Moon JH, Kim H, Kim JS, Hwang YY, Intragumtornchai T, *et al.* Nonbacterial infections in Asian patients treated with alemtuzumab: a retrospective study of the Asian Lymphoma Study Group. *Leuk Lymphoma* 2012; **53**:1515–1524.
45. Ahn IE, Jerussi T, Farooqui M, Tian X, Wiestner A, Gea-Banacloche J. Atypical *Pneumocystis jirovecii* pneumonia in previously untreated patients with CLL on single-agent ibrutinib. *Blood* 2016; **128**:1940–1943.
46. Anovazzi G, Medeiros MC, Pigossi SC, Finoti LS, Souza Moreira TM, Mayer MP, *et al.* Functionality and opposite roles of two interleukin 4 haplotypes in immune cells. *Genes Immun* 2017; **18**:33–41.

47. Imran M, Laddha NC, Dwivedi M, Mansuri MS, Singh J, Rani R, et al. **Interleukin-4 genetic variants correlate with its transcript and protein levels in patients with vitiligo.** *Br J Dermatol* 2012; **167**:314–323.
48. Li J, Lin LH, Wang J, Peng X, Dai HR, Xiao H, et al. **Interleukin-4 and interleukin-13 pathway genetics affect disease susceptibility, serum immunoglobulin E levels, and gene expression in asthma.** *Ann Allergy Asthma Immunol* 2014; **113**:173–179.e1.
49. Akkad DA, Arning L, Ibrahim SM, Epplen JT. **Sex specifically associated promoter polymorphism in multiple sclerosis affects interleukin 4 expression levels.** *Genes Immun* 2007; **8**:703–706.
50. Hussein YM, El-Shal AS, Rezk NA, Abdel Galil SM, Alzahrani SS. **Influence of interleukin-4 gene polymorphisms and interleukin-4 serum level on susceptibility and severity of rheumatoid arthritis in Egyptian population.** *Cytokine* 2013; **61**:849–855.
51. Bozza A, Reis BS, Pereira PP, Pedrosa EP, Goes AM. **Interferon-gamma and interleukin-4 single nucleotide gene polymorphisms in paracoccidioidomycosis.** *Cytokine* 2009; **48**:212–217.
52. Kim BS, Park SM, Uhm TG, Kang JH, Park JS, Jang AS, et al. **Effect of single nucleotide polymorphisms within the interleukin-4 promoter on aspirin intolerance in asthmatics and interleukin-4 promoter activity.** *Pharmacogenet Genomics* 2010; **20**:748–758.
53. Babula O, Lazdane G, Kroica J, Linhares IM, Ledger WJ, Witkin SS. **Frequency of interleukin-4 (IL-4) -589 gene polymorphism and vaginal concentrations of IL-4, nitric oxide, and mannose-binding lectin in women with recurrent vulvovaginal candidiasis.** *Clin Infect Dis* 2005; **40**:1258–1262.
54. Choi EH, Lee HJ, Yoo T, Chanock SJ. **A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children.** *J Infect Dis* 2002; **186**:1207–1211.
55. Forton JT, Rowlands K, Rockett K, Hanchard N, Herbert M, Kwiatkowski DP, et al. **Genetic association study for RSV bronchiolitis in infancy at the 5q31 cytokine cluster.** *Thorax* 2009; **64**:345–352.
56. Hoebee B, Rietveld E, Bont L, Oosten M, Hodemaekers HM, Nagelkerke NJ, et al. **Association of severe respiratory syncytial virus bronchiolitis with interleukin-4 and interleukin-4 receptor alpha polymorphisms.** *J Infect Dis* 2003; **187**:2–11.
57. Zhang M, Lu Y, Zhang X, Lu A, Wang L, Chen C. **Interleukin-4 polymorphism is associated with severity of respiratory syncytial virus infection.** *J Paediatr Child Health* 2016; **52**:25–29.
58. Vafa M, Maiga B, Israelsson E, Dolo A, Doumbo OK, Troye-Blomberg M. **Impact of the IL-4-590 C/T transition on the levels of *Plasmodium falciparum* specific IgE, IgG, IgG subclasses and total IgE in two sympatric ethnic groups living in Mali.** *Microbes Infect* 2009; **11**:779–784.
59. Rasouli M, Kiany S. **Association of interferon-gamma and interleukin-4 gene polymorphisms with susceptibility to brucellosis in Iranian patients.** *Cytokine* 2007; **38**:49–53.
60. Connelly TM, Koltun WA, Sangster W, Berg AS, Hegarty JP, Harris L 3rd, et al. **An interleukin-4 polymorphism is associated with susceptibility to *Clostridium difficile* infection in patients with inflammatory bowel disease: results of a retrospective cohort study.** *Surgery* 2014; **156**:769–774.
61. Anovazzi G, Kim YJ, Viana AC, Curtis KM, Orrico SR, Cirelli JA, et al. **Polymorphisms and haplotypes in the interleukin-4 gene are associated with chronic periodontitis in a Brazilian population.** *J Periodontol* 2010; **81**:392–402.
62. Gonzales JR, Kobayashi T, Michel J, Mann M, Yoshie H, Meyle J. **Interleukin-4 gene polymorphisms in Japanese and Caucasian patients with aggressive periodontitis.** *J Clin Periodontol* 2004; **31**:384–389.
63. Gonzales JR, Mann M, Stelzig J, Bodeker RH, Meyle J. **Single-nucleotide polymorphisms in the IL-4 and IL-13 promoter region in aggressive periodontitis.** *J Clin Periodontol* 2007; **34**:473–479.
64. Holla LI, Fassmann A, Augustin P, Halabala T, Znojil V, Vanek J. **The association of interleukin-4 haplotypes with chronic periodontitis in a Czech population.** *J Periodontol* 2008; **79**:1927–1933.
65. Loo WT, Fan CB, Bai LJ, Yue Y, Dou YD, Wang M, et al. **Gene polymorphism and protein of human pro- and anti-inflammatory cytokines in Chinese healthy subjects and chronic periodontitis patients.** *J Transl Med* 2012; **10** (Suppl 1):S8.
66. Cenci E, Mencacci A, Del Sero G, Bacci A, Montagnoli C, d'Ostiani CF, et al. **Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses.** *J Infect Dis* 1999; **180**:1957–1968.
67. Hernandez-Pando R, Aguilar D, Hernandez ML, Orozco H, Rook G. **Pulmonary tuberculosis in BALB/c mice with non-functional IL-4 genes: changes in the inflammatory effects of TNF-alpha and in the regulation of fibrosis.** *Eur J Immunol* 2004; **34**:174–183.
68. Fischer JE, Johnson JE, Kuli-Zade RK, Johnson TR, Aung S, Parker RA, et al. **Overexpression of interleukin-4 delays virus clearance in mice infected with respiratory syncytial virus.** *J Virol* 1997; **71**:8672–8677.
69. Tang YW, Graham BS. **Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.** *J Clin Invest* 1994; **94**:1953–1958.
70. Himmelrich H, Launois P, Maillard I, Biedermann T, Tacchini-Cottier F, Locksley RM, et al. **In BALB/c mice, IL-4 production during the initial phase of infection with *Leishmania* major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease.** *J Immunol* 2000; **164**:4819–4825.